MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./320/0.1/20.12.24 Stock

Warrant

DE000MG03862

Real-time Bid/Ask 05:07:22 2024-05-21 EDT
0.084 EUR / 0.165 EUR +26.26% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./320/0.1/20.12.24
Current month-40.72%
1 month-37.74%
Date Price Change
24-05-21 0.086 -13.13%
24-05-20 0.099 -1.00%
24-05-17 0.1 -10.71%
24-05-16 0.112 +6.67%
24-05-15 0.105 -2.78%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 02:11 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN MG0386
ISINDE000MG03862
Date issued 2024-03-12
Strike 320 $
Maturity 2024-12-20 (214 Days)
Parity 10 : 1
Emission price 0.17
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.26
Lowest since issue 0.086
Spread 0.076
Spread %46.91%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
237.1 USD
Average target price
279 USD
Spread / Average Target
+17.66%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW